

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

FORESIGHT DIAGNOSTICS INC.,
Petitioner,

v.

PERSONALIS, INC.,
Patent Owner.

Case No. IPR2024-00170
U.S. Patent No. 11,584,968

PETITIONER'S UPDATED EXHIBIT LIST

Mail Stop: PATENT BOARD
Patent Trial and Appeal Board
U.S. Patent & Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

PETITIONER'S EXHIBIT LIST

EX1001	U.S. Patent No. 10,584,968 issued to West
EX1002	Rebecca J. Leary <i>et al.</i> , “Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing,” <i>Science Translational Medicine</i> (2010) (Leary)
EX1003	Quake <i>et al.</i> , WO 2011/057061 (Quake)
EX1004	Reserved
EX1005	Andreas Gnirke <i>et al.</i> , “Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing,” <i>Nature Biotechnology</i> (2009) (Gnirke)
EX1006	Florian Mertes <i>et al.</i> , “Targeted enrichment of genomic DNA regions for next-generation sequencing, Briefings in Functional Genomics,” <i>Briefings in Functional Genomics</i> (2011) (Mertes)
EX1007	Lira Mamanova <i>et al.</i> , “Target-enrichment strategies for next-generation sequencing,” <i>Nature</i> (2010) (Mamanova)
EX1008	Chan et al., “Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing,” <i>Clinical Chemistry</i> , January 1, 2013
EX1009	Reserved
EX1010	<i>Personalis v. Foresight</i> , First Amended Complaint, D. Colo., Case No. 1:22-v-01913, Dkt. 9, filed August, 17, 2022 (“FAC”)
EX1011	Reserved
EX1012	Timothy J. Ley <i>et al.</i> , “DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome,” <i>Nature</i> (2008) (Ley)
EX1013	Jay Shendure & Hanlee Ji, “Next-generation DNA sequencing,” <i>Nature Biotechnology</i> (2008) (Shendure)

EX1014	Jeffrey S. Ross and Maureen Cronin, “Whole Cancer Genome Sequencing by Next-Generation Methods,” <i>American Journal of Clinical Pathology</i> (2011) (Ross)
EX1015	David J. McBride, et al., “Use of Cancer-Specific Genomic Rearrangements to Quantify Disease Burden in Plasma from Patients with Solid Tumors,” <i>Genes, Chromosomes & Cancer</i> (2010) (McBride)
EX1016- EX1020	Reserved
EX1021	Declaration of Ingrid Hsieh-Yee, Ph.D.
EX1022	Reserved
EX1023	<i>Curriculum Vitae</i> of John Quackenbush
EX1024	https://www.garvan.org.au/research/kinghorn-centre-for-clinical-genomics/learn-about-genomics/for-gp/genetics-refresher-1/types-of-variants
EX1025	Reserved
EX1026	Reserved
EX1027	Hugo Lam, et al., “Performance comparison of whole-genome sequencing platforms,” <i>Nature Biotechnology</i> (2012) (Lam)
EX1028	Illumina, Technical Note: Sequencing
EX1029	Illumina, Specification Sheet: Illumina Sequencing
EX1030	Reserved
EX1031	Matthew Meyerson, et al., “Advances in understanding cancer genomes through second-generation sequencing,” <i>Nature Reviews</i> (2010) (Meyerson)
EX1032	Reserved

EX1033- EX1036	Reserved
EX1037	Infringement Claim Chart for U.S. Patent No. 10,450,611; Ex. D to Patent Owner's FAC
EX1038	Reserved
EX1039	Reserved
EX1040	D. Sims <i>et al.</i> , "Sequencing depth and coverage: key considerations in genomic analyses," Nature Reviews: Genetics (2014) (<i>Sims</i>)
EX1041	Reserved
EX1042	Ley Supplemental Information
EX1043	A. Newman <i>et al.</i> , "Integrated digital error suppression for improved detection of circulating tumor DNA," Nature Biotechnology (2016) (<i>Newman</i>)
EX1044	A. Newman <i>et al.</i> , "An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage," Nature Medicine (2014) (<i>Newman 2014</i>)
EX1045- EX1069	Reserved
EX1070	S. Dawson, <i>et al.</i> , "Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer," New England Journal of Medicine (2013) (<i>Dawson</i>)
EX1071- EX1076	Reserved
EX1077	D. Bentley, et al., "Accurate whole human genome sequencing using reversible terminator chemistry," Nature (2008) (<i>Bentley</i>)
EX1078	
EX1079- EX1099	Reserved

EX1100	Declaration of John Quackenbush, Ph.D.
EX1101	J. Okosun, <i>et al.</i> , "Whole Genome Sequencing in Sequential Biopsies Reveals the Genetic Evolution of Follicular Lymphoma," Blood (2012) 120 (21) 145 (Okosun I)
EX1102	J. Okosun, <i>et al.</i> , "Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma," Nature America (2014) (Okosun II)
EX1103	Michael A. Chapman, <i>et al.</i> , "Initial genome sequencing and analysis of multiple myeloma, Nature (2011)
EX1104	William Lee, <i>et al.</i> , "The mutation spectrum revealed by paired genome sequences from a lung cancer patient," 27 May 2010 (Lee 2010)
EX1105	Li Ding <i>et al.</i> , "Genome remodelling in a basal-like breast cancer metastasis and xenograft," Nature (2010) (Ding 2010)
EX1106	Yan-Fang Guan, <i>et al.</i> , "Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer," Chinese J Cancer, 2012 Oct. 31 (10):463-470 (Guan)
EX1107	<i>Personalis v. Foresight</i> , First Amended Complaint, D. Colo., Case No. 1:23-cv-01623, Dkt. 21, filed August, 31, 2023
EX1108	Prosecution File History of Appl. 17/494,513 (Pat. No. 11,584,968)
EX1109	QIAamp® DNA Mini Kit and QIAamp DNA Blood Mini Kit Handbook, Feb. 2003 (Qiagen Protocol)
EX1110	Fluidigm, Specification Sheet for Access Array™ System, October 2012
EX1111	S. Hohaus, <i>et al.</i> , "Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas," ScienceDirect, Aug. 2009 https://www.sciencedirect.com/science/article/pii/S0923753419409575
EX1112	U.S. Publication No. 2022/0195530, issued to Diehn <i>et al.</i> , (Diehn-530)

EX1113	Supplementary Information (from Okosun II)
EX1114	Furneaux Declaration (from IPR2023-00224, -00317)
EX1115	West Declaration (from IPR2023-00224, -00317)
EX1116	Patent Owner Response from IPR2023-00224
EX1117	Dawson Supplementary Materials
EX1118	Christopher T. Saunders, <i>et al.</i> , "Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs, Bioinformatics, May 10, 2012
EX1119	Ex. F. to First Amended Complaint (Case 2)
EX1120	Safia Danovi, "A sequencing revolution in cancer," Milestones, Milestone 6, Nature, February 2021
EX1121	<i>Personalis v. Foresight</i> , Defendant's Opposition to Motion to Consolidate Related Cases, D. Colo., Case No. 1:22-cv-01913, Dkt. 63, filed Oct. 20, 2023
EX1122	Patent Owner Preliminary Response from IPR2023-00224 ('394)
EX1123	Patent Owner Preliminary Response from IPR2024-00170 ('033)
EX1124	Patent Owner Response from IPR2024-00170 ('033)
EX1125	USPTO Proposed Rules (88 Fed. Reg. 24503)
EX1126	<i>Personalis v. Foresight</i> , Personalis' Opposition to Defendant's Motion to Consolidate Related Cases, D. Colo., Case No. 1:22-cv-01913, Dkt. 66-1
EX1127	Furneaux Declaration (from IPR2023-00224)

IPR2024-00170
U.S. Patent No. 11,584,968

Dated: March 19, 2024

Respectfully submitted,

/Andrew E. Krause/

Andrew E. Krause, Reg. No. 76,276

Alan J. Heinrich (*pro hac vice* to be requested)

IRELL & MANELLA LLP

1800 Avenue of the Stars, Ste. 900

Los Angeles, CA 90067

(310) 203-7668

akrause@irell.com

Amir Naini, Reg. No. 45,770

NAINI P.C.

2632 Wilshire Blvd., Suite 268

Santa Monica, CA 90403

(310) 592-3030

amir@nainipc.com

Attorneys for Petitioner

Foresight Diagnostics Inc.

CERTIFICATE OF SERVICE

I hereby certify, pursuant to 37 C.F.R. section 42.6, that on March 19, 2024, a complete copy of the foregoing document **PETITIONER'S UPDATED EXHIBIT LIST** and **EX1127** were served upon the following, by ELECTRONIC MAIL:

Nathanel Luman, Reg. No. 63,160
BoxPersonalis968@knobbe.com

Derek C. Walter, Reg. No. 74,656
Personalis.Foresight@weil.com

/Susan M. Langworthy/
Susan M. Langworthy